IL5 and chronic rhinosinusitis with nasal polyps: As anti-IL-5 biological agents were introduced as a new-line treatment for patients affected by SEA, the finding of a concomitant sinonasal therapeutic effect in patients with comorbid CRSwNP has sparked interest in the application of such drugs as a possible breakthrough treatment in patients with type 2 eosinophilic difficult-to-treat nasal polyposis.